Characterization of GABAergic Marker Expression in the Chronic Unpredictable Stress Model of Depression

Background Evidence continues to build suggesting that the GABAergic neurotransmitter system is altered in brains of patients with major depressive disorder. However, there is little information available related to the extent of these changes or the potential mechanisms associated with these alterations. As stress is a well-established precipitant to depressive episodes, we sought to explore the impact of chronic stress on GABAergic interneurons. Methods Using western blot analyses and quantitative real-time polymerase chain reaction, we assessed the effects of five-weeks of chronic unpredictable stress exposure on the expression of GABA-synthesizing enzymes (GAD65 and GAD67), calcium-binding proteins (calbindin, parvalbumin, and calretinin), and neuropeptides co-expressed in GABAergic neurons (somatostatin, neuropeptide Y, vasoactive intestinal peptide, and cholecystokinin) in the prefrontal cortex and hippocampus of rats. We also investigated the effects of corticosterone and dexamethasone exposure on these markers in vitro in primary cortical and hippocampal cultures. Results We found that chronic unpredictable stress induced significant reductions of GAD67 protein levels in both the prefrontal cortex and hippocampus of chronic unpredictable stress-exposed rats but did not detect changes in GAD65 protein expression. Similar protein expression changes were found in vitro in cortical neurons. In addition, our results provide clear evidence of reduced markers of interneuron population(s), namely somatostatin and neuropeptide Y, in the prefrontal cortex, suggesting these cell types may be selectively vulnerable to chronic stress. Conclusion Together, this work highlights that chronic stress induces regional and cell type-selective effects on GABAergic interneurons in rats. These findings provide additional supporting evidence that stress-induced GABA neuron dysfunction and cell vulnerability play critical roles in the pathophysiology of stress-related illnesses, including major depressive disorder.

[1]  Etienne Sibille,et al.  Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives , 2017, Biological Psychiatry.

[2]  R. Duman,et al.  Prefrontal cortex GABAergic deficits and circuit dysfunction in the pathophysiology and treatment of chronic stress and depression , 2017, Current Opinion in Behavioral Sciences.

[3]  E. Sibille.  Reduced Somatostatin Expression or Somatostatin-Positive Gamma-Aminobutyric Acid Neurons: A Shared Pathology Across Brain Disorders , 2017, Biological Psychiatry.

[4]  D. Béracochéa,et al.  Roles of Hippocampal Somatostatin Receptor Subtypes in Stress Response and Emotionality , 2017, Neuropsychopharmacology.

[5]  B. Orser,et al.  Sex-Dependent Anti-Stress Effect of an α5 Subunit Containing GABAA Receptor Positive Allosteric Modulator , 2016, Front. Pharmacol..

[6]  T. Fuchs,et al.  Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state , 2016, Molecular Psychiatry.

[7]  R. Tremblay,et al.  GABAergic Interneurons in the Neocortex: From Cellular Properties to Circuits , 2016, Neuron.

[8]  F. J. A. Aguilar,et al.  Chronic unpredictable mild stress generates oxidative stress and systemic inflammation in rats , 2016, Physiology & Behavior.

[9]  C. Liston,et al.  Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy. , 2016, Journal of psychiatry & neuroscience : JPN.

[10]  E. Sibille,et al.  Somatostatin, neuronal vulnerability and behavioral emotionality , 2014, Molecular Psychiatry.

[11]  C. Liston,et al.  TMS over the left dorsolateral prefrontal cortex increases GABA concentration in the ventromedial prefrontal cortex in major depression , 2014 .

[12]  Amy R. Johnson,et al.  In vivo 1H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder , 2014, Neuroscience Letters.

[13]  Jutta Joormann,et al.  COGNITIVE PROCESSES AND EMOTION REGULATION IN DEPRESSION , 2014, Depression and anxiety.

[14]  Etienne Sibille,et al.  Opposing Effects of Acute versus Chronic Blockade of Frontal Cortex Somatostatin-Positive Inhibitory Neurons on Behavioral Emotionality in Mice , 2014, Neuropsychopharmacology.

[15]  J. Nacher,et al.  Chronic stress alters inhibitory networks in the medial prefrontal cortex of adult mice , 2013, Brain Structure and Function.

[16]  Paul B. Fitzgerald,et al.  A meta-analysis of cortical inhibition and excitability using transcranial magnetic stimulation in psychiatric disorders , 2013, Clinical Neurophysiology.

[17]  C. Belzung,et al.  Models of Depression: Unpredictable Chronic Mild Stress in Mice , 2013, Current protocols in pharmacology.

[18]  K. Nakazawa,et al.  Social Isolation Exacerbates Schizophrenia-Like Phenotypes via Oxidative Stress in Cortical Interneurons , 2013, Biological Psychiatry.

[19]  E. Tobe.  Mitochondrial dysfunction, oxidative stress, and major depressive disorder , 2013, Neuropsychiatric disease and treatment.

[20]  A. Lussier,et al.  Altered GABAergic and glutamatergic activity within the rat hippocampus and amygdala in rats subjected to repeated corticosterone administration but not restraint stress , 2013, Neuroscience.

[21]  J. Licinio,et al.  Pathological parainflammation and endoplasmic reticulum stress in depression: potential translational targets through the CNS insulin, klotho and PPAR-γ systems , 2013, Molecular Psychiatry.

[22]  A. Ciobica,et al.  The relevance of oxidative stress status in first episode and recurrent depression. , 2012, Journal of affective disorders.

[23]  E. Sibille,et al.  Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. , 2012, The American journal of psychiatry.

[24]  B. Gorzalka,et al.  Neurobiology of chronic mild stress: Parallels to major depression , 2012, Neuroscience & Biobehavioral Reviews.

[25]  R. Shelton,et al.  Oxidative stress and glutathione response in tissue cultures from persons with major depression. , 2012, Journal of psychiatric research.

[26]  G. Fishell,et al.  The origin of neocortical nitric oxide synthase-expressing inhibitory neurons , 2012, Front. Neural Circuits.

[27]  G. Rajkowska,et al.  Decreased Expression of Synapse-Related Genes and Loss of Synapses in Major Depressive Disorder , 2012, Nature Medicine.

[28]  N. Negrev,et al.  Lateralized hippocampal effects of vasoactive intestinal peptide on learning and memory in rats in a model of depression , 2012, Psychopharmacology.

[29]  H. Son,et al.  Neuropathological abnormalities of astrocytes, GABAergic neurons, and pyramidal neurons in the dorsolateral prefrontal cortices of patients with major depressive disorder , 2012, European Neuropsychopharmacology.

[30]  M. Mannervik,et al.  Neuropeptide Y: Identification of a novel rat mRNA splice-variant that is downregulated in the hippocampus and the prefrontal cortex of a depression-like model , 2012, Peptides.

[31]  T. Sejnowski,et al.  Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia , 2012, Neuropharmacology.

[32]  JaneR . Taylor,et al.  Gene Profiling Reveals a Role for Stress Hormones in the Molecular and Behavioral Response to Food Restriction , 2012, Biological Psychiatry.

[33]  Benjamin A. Ely,et al.  Anterior cingulate cortex γ-aminobutyric acid in depressed adolescents: relationship to anhedonia. , 2012, Archives of general psychiatry.

[34]  J. Nacher,et al.  Expression of PSA-NCAM and synaptic proteins in the amygdala of psychiatric disorder patients. , 2012, Journal of psychiatric research.

[35]  Oscar Marín,et al.  Interneuron dysfunction in psychiatric disorders , 2012, Nature Reviews Neuroscience.

[36]  M. Papp,et al.  Different pattern of changes in calcium binding proteins immunoreactivity in the medial prefrontal cortex of rats exposed to stress models of depression , 2011, Pharmacological reports : PR.

[37]  H. M. Morris,et al.  GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. , 2011, The international journal of neuropsychopharmacology.

[38]  G. Northoff,et al.  Discovering imaging endophenotypes for major depression , 2011, Molecular Psychiatry.

[39]  Nanxin Li,et al.  Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure , 2011, Biological Psychiatry.

[40]  B Luscher,et al.  The GABAergic deficit hypothesis of major depressive disorder , 2011, Molecular Psychiatry.

[41]  E. Sibille,et al.  Reduced somatostatin in subgenual anterior cingulate cortex in major depression , 2011, Neurobiology of Disease.

[42]  D. Treit,et al.  Anxiolytic-like effects of somatostatin isoforms SST 14 and SST 28 in two animal models (Rattus norvegicus) after intra-amygdalar and intra-septal microinfusions , 2011, Psychopharmacology.

[43]  S. Chaki,et al.  Pharmacological characterization of repeated corticosterone injection-induced depression model in rats , 2010, Brain Research.

[44]  M. Papp,et al.  Alterations in hippocampal calcium-binding neurons induced by stress models of depression: a preliminary assessment , 2010, Pharmacological reports : PR.

[45]  H. Schmidt,et al.  A negative regulator of MAP kinase causes depressive behavior. , 2010, Nature medicine.

[46]  G. Rajkowska,et al.  Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. , 2010, The international journal of neuropsychopharmacology.

[47]  K. Behar,et al.  Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole , 2010, Molecular Psychiatry.

[48]  S. Totterdell,et al.  Sustained stress-induced changes in mice as a model for chronic depression , 2010, Psychopharmacology.

[49]  S. Rotzinger,et al.  Behavioral effects of neuropeptides in rodent models of depression and anxiety , 2010, Peptides.

[50]  B. Czéh,et al.  Stress Impairs GABAergic Network Function in the Hippocampus by Activating Nongenomic Glucocorticoid Receptors and Affecting the Integrity of the Parvalbumin-Expressing Neuronal Network , 2010, Neuropsychopharmacology.

[51]  G. Rajkowska,et al.  Reduced Density of Calbindin Immunoreactive GABAergic Neurons in the Occipital Cortex in Major Depression: Relevance to Neuroimaging Studies , 2010, Biological Psychiatry.

[52]  Paul B. Fitzgerald,et al.  Evidence of Cortical Inhibitory Deficits in Major Depressive Disorder , 2010, Biological Psychiatry.

[53]  K. Krause,et al.  Involvement of NOX2 in the Development of Behavioral and Pathologic Alterations in Isolated Rats , 2009, Biological Psychiatry.

[54]  J. Harro,et al.  Increased Vulnerability to Depressive-Like Behavior of Mice with Decreased Expression of VGLUT1 , 2009, Biological Psychiatry.

[55]  D. Treit,et al.  Anxiolytic and antidepressant actions of somatostatin: the role of sst2 and sst3 receptors , 2009, Psychopharmacology.

[56]  A. Shalaby,et al.  Effect of Escitalopram on GABA level and anti-oxidant markers in prefrontal cortex and nucleus accumbens of chronic mild stress-exposed albino rats. , 2009, International journal of physiology, pathophysiology and pharmacology.

[57]  Dennis S. Charney,et al.  Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder , 2009, Biological Psychiatry.

[58]  B. McEwen,et al.  Dynamic regulation of mitochondrial function by glucocorticoids , 2009, Proceedings of the National Academy of Sciences.

[59]  B. Bogerts,et al.  Suicide and depression in the quantitative analysis of glutamic acid decarboxylase-Immunoreactive neuropil. , 2009, Journal of affective disorders.

[60]  C. Dickson,et al.  Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: Behavioral and neurophysiological evidence , 2008, Neuroscience.

[61]  M. Hamon,et al.  Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin , 2008, Molecular Psychiatry.

[62]  JaneR . Taylor,et al.  Chronic Unpredictable Stress Decreases Cell Proliferation in the Cerebral Cortex of the Adult Rat , 2007, Biological Psychiatry.

[63]  Reidun Ursin,et al.  Extracellular levels of serotonin and GABA in the hippocampus after chronic mild stress in rats. A microdialysis study in an animal model of depression , 2007, Behavioural Brain Research.

[64]  G. Sanacora,et al.  GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. , 2007, CNS & neurological disorders drug targets.

[65]  A. Sarandol,et al.  Major depressive disorder is accompanied with oxidative stress: short‐term antidepressant treatment does not alter oxidative–antioxidative systems , 2007, Human psychopharmacology.

[66]  G. Rajkowska,et al.  GABAergic Neurons Immunoreactive for Calcium Binding Proteins are Reduced in the Prefrontal Cortex in Major Depression , 2007, Neuropsychopharmacology.

[67]  Gregor Hasler,et al.  Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. , 2007, Archives of general psychiatry.

[68]  Olga V. Demler,et al.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[69]  S. Fatemi,et al.  GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum , 2005, Schizophrenia Research.

[70]  John H Krystal,et al.  Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. , 2004, Archives of general psychiatry.

[71]  M. Åsberg,et al.  Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. , 2004, Journal of psychiatric research.

[72]  P. Brambilla,et al.  GABAergic dysfunction in mood disorders , 2003, Molecular Psychiatry.

[73]  C. Beasley,et al.  Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins , 2002, Biological Psychiatry.

[74]  C. Beasley,et al.  The density and spatial distribution of gabaergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia , 2002, Biological Psychiatry.

[75]  J. Herman,et al.  Differential regulation of forebrain glutamic acid decarboxylase mRNA expression by aging and stress , 2001, Brain Research.

[76]  Carmine M Pariante,et al.  Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment , 2001, Biological Psychiatry.

[77]  M. Hamon,et al.  Enhanced Cortical Extracellular Levels of Cholecystokinin-Like Material in a Model of Anticipation of Social Defeat in the Rat , 2001, The Journal of Neuroscience.

[78]  P. Holmes,et al.  Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. , 2000, European journal of pharmacology.

[79]  Fahmeed Hyder,et al.  Reduced Cortical γ-Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy , 1999 .

[80]  K. Fuxe,et al.  Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression , 1999, Neuroscience Letters.

[81]  M. Heilig,et al.  Decreased experimental anxiety and voluntary ethanol consumption in rats following central but not basolateral amygdala lesions , 1997, Brain Research.

[82]  T. Yagi,et al.  Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[83]  T. Yagi,et al.  Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. , 1996, Biochemical and biophysical research communications.

[84]  H. Meltzer,et al.  Neuropeptide Y in Frontal Cortex Is Not Altered in Major Depression , 1995, Journal of neurochemistry.

[85]  A. Rush,et al.  Low plasma γ-aminobutyric acid levels in male patients with depression , 1992, Biological Psychiatry.

[86]  G. Ordway,et al.  Reduced Neuropeptide Y Concentrations in Suicide Brain , 1992, Journal of neurochemistry.

[87]  C. Nemeroff,et al.  Cerebrospinal fluid neuropeptides in mood disorder and dementia. , 1992, Journal of affective disorders.

[88]  M. Erlander,et al.  The structural and functional heterogeneity of glutamic acid decarboxylase: A review , 1991, Neurochemical Research.

[89]  W. Berrettini,et al.  Neuroactive Substances in Cerebrospinal Fluid , 1988 .

[90]  J. Kelsoe,et al.  Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[91]  H. Ågren,et al.  Low levels of somatostatin in human CSF mark depressive episodes , 1984, Psychoneuroendocrinology.

[92]  S. Otsuki,et al.  Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. , 1982, Biological psychiatry.

[93]  E. Sibille,et al.  Somatostatin-positive GABA Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives , 2017 .

[94]  Benjamin A. Ely,et al.  Anterior Cingulate Cortex -Aminobutyric Acid in Depressed Adolescents , 2015 .

[95]  G. Fishell,et al.  Three groups of interneurons account for nearly 100% of neocortical GABAergic neurons , 2011, Developmental neurobiology.

[96]  J. Price,et al.  Neurocircuitry of Mood Disorders , 2010, Neuropsychopharmacology.

[97]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[98]  K. Kendler,et al.  A Swedish national twin study of lifetime major depression. , 2006, The American journal of psychiatry.

[99]  B. Czéh,et al.  Chronic Stress Decreases the Number of Parvalbumin-Immunoreactive Interneurons in the Hippocampus: Prevention by Treatment with a Substance P Receptor (NK1) Antagonist , 2005, Neuropsychopharmacology.

[100]  J. Krystal,et al.  Reduced Cortical g -Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy , 1999 .

[101]  R. Kessler,et al.  The effects of stressful life events on depression. , 1997, Annual review of psychology.

[102]  D. Rubinow,et al.  Neuroactive substances in cerebrospinal fluid. Normal and pathological regulatory mechanisms. , 1988, Annals of the New York Academy of Sciences.

[103]  C. Wahlestedt,et al.  Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. , 1988, Journal of psychiatric research.